Key Takeaways: The Eleventh Circuit recently upheld a surgeon’s conviction, prison sentence and forfeiture for false ownership disclosures on a CMS-855 Medicare enrollment form, reinforcing that inaccurate enrollment information can carry criminal consequences. The court confirmed that CMS-855 accuracy is not limited to initial enrollment but extends to every submission, including routine updates and revalidations. Providers and suppliers should implement robust CMS-855 verification and oversight controls across all submissions, with a focus on accuracy, consistency and accountability. The U.S. Court of Appeals for the Eleventh Circuit recently upheld an orthopedic surgeon’s conviction, nearly three-year prison sentence and forfeiture of $125,000 for making a false statement, in violation of 18 U.S.C. § 1035, on a Medicare enrollment application.1 This case underscores how false ownership disclosures by

Key Takeaways: FDA will convene the Pharmacy Compounding Advisory Committee (PCAC) on July 23-24, 2026, to discuss seven peptides for potential inclusion on the 503A bulks list. An additional five peptides will be considered at a PCAC meeting to be held before the end of Feb. 2027. FDA separately announced on April 15, 2026, that these same substances will be removed from 503A Category 2 after seven calendar days because the nominations were withdrawn, although the agency confirmed it was still planning to bring them to PCAC. That procedural removal should not be read as a go-ahead to compound these peptides. Under FDA's current policy, removal of a bulk drug substance from Category 2 does not, on its own, authorize use of that